Notice of Results

RNS Number : 9302Q

Hikma Pharmaceuticals Plc

03 March 2016

 

Notice of Results

LONDON, UK, 3 March, 2016 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing pharmaceuticals company, will announce its annual financial results for the year ended 31 December 2015 on Wednesday 16 March 2016.

A presentation and webcast for analysts will be held at 9.30am GMT at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.

To join via conference call please dial: [phone]

UK Toll‐Free Number: 0808 109 0700

The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://cache.merchantcantos.com/webcast/webcaster/4000/7464/16532/58467/Lobby/default.htm 

Playback facility:

A playback of the conference call will be available up to 7 days after the presentation.

UK & International Number: [phone]

UK Toll-Free Number: 0800 633 8453

Replay PIN code: 8022823#

-Ends-

Enquiries

Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations	[phone]/[phone]
Zeena Murad, Investor Relations Manager	[phone]/[phone]
FTI Consulting
Ben Atwell/Matthew Cole	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of US$1,489 million and profit attributable to shareholders of US$299 million.

 

END

 

 

NORZMGGFLFGGVZG